Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune, inflammatory, and allergic diseases. The company develops the LYTAC platform, a modular technology designed to create th…
| Métrica | LYCA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.7% | — |
| Operating Margin | — | -31.5% | — |
| Net Margin | — | -30.4% | — |
| FCF Margin | — | -10.6% | — |
| ROE | — | -36.3% | — |
| ROA | — | -30.0% | — |
| Current Ratio | — | 2.68 | — |
| Debt / Equity | — | 0.28 | — |
Lycia Therapeutics, Inc. cotiza a 25.05 USD y tiene una capitalización bursátil de $1.3B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud